These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 8648870)
1. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. Simon GE; VonKorff M; Heiligenstein JH; Revicki DA; Grothaus L; Katon W; Wagner EH JAMA; 1996 Jun; 275(24):1897-902. PubMed ID: 8648870 [TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Simon GE; Heiligenstein J; Revicki D; VonKorff M; Katon WJ; Ludman E; Grothaus L; Wagner E Arch Fam Med; 1999; 8(4):319-25. PubMed ID: 10418538 [TBL] [Abstract][Full Text] [Related]
3. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care? Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM; J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. Revicki DA; Brown RE; Keller MB; Gonzales J; Culpepper L; Hales RE J Clin Psychiatry; 1997 Feb; 58(2):47-58. PubMed ID: 9062373 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. Serrano-Blanco A; Gabarron E; Garcia-Bayo I; Soler-Vila M; Caramés E; Peñarrubia-Maria MT; Pinto-Meza A; Haro JM; J Affect Disord; 2006 Apr; 91(2-3):153-63. PubMed ID: 16458976 [TBL] [Abstract][Full Text] [Related]
6. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Simon GE; Heiligenstein JH; Grothaus L; Katon W; Revicki D J Clin Psychiatry; 1998 Feb; 59(2):49-55. PubMed ID: 9501885 [TBL] [Abstract][Full Text] [Related]
7. Economic appraisal of citalopram in the management of single-episode depression. Sclar DA; Skaer TL; Robison LM; Galin RS J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508 [TBL] [Abstract][Full Text] [Related]
8. Study addresses question of preferred initial therapy for depression. Am J Health Syst Pharm; 1996 Sep; 53(17):1994. PubMed ID: 8870882 [No Abstract] [Full Text] [Related]
9. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670 [TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362 [TBL] [Abstract][Full Text] [Related]
11. Effect of antidepressant therapy on health care utilization and costs in primary care. Croghan TW; Lair TJ; Engelhart L; Crown WE; Copley-Merriman C; Melfi CA; Obenchain RL; Buesching DP Psychiatr Serv; 1997 Nov; 48(11):1420-6. PubMed ID: 9355169 [TBL] [Abstract][Full Text] [Related]
12. TCAs or SSRIs as initial therapy for depression? Tyra JM; Greenawald MH J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616 [No Abstract] [Full Text] [Related]
13. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Lapierre Y; Bentkover J; Schainbaum S; Manners S Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716 [TBL] [Abstract][Full Text] [Related]
14. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180 [TBL] [Abstract][Full Text] [Related]
15. Modelling the cost effectiveness of antidepressant treatment in primary care. Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081 [TBL] [Abstract][Full Text] [Related]
16. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Sclar DA; Robison LM; Skaer TL; Legg RF; Nemec NL; Galin RS; Hughes TE; Buesching DP Clin Ther; 1994; 16(4):715-30; discussion 74. PubMed ID: 7982260 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Lenox-Smith A; Greenstreet L; Burslem K; Knight C Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria. Brown MC; Nimmerrichter AA; Guest JF Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. Patel V; Chisholm D; Rabe-Hesketh S; Dias-Saxena F; Andrew G; Mann A Lancet; 2003 Jan; 361(9351):33-9. PubMed ID: 12517464 [TBL] [Abstract][Full Text] [Related]